Apnimed to Participate in the William Blair Virtual Conference: Transitioning Biotech Breakthroughs to Commercial Success
12 juil. 2023 08h00 HE | Apnimed, Inc.
CAMBRIDGE, Mass., July 12, 2023 (GLOBE NEWSWIRE) -- Apnimed, Inc., a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies for the treatment of obstructive sleep...
Apnimed Presented Positive Phase 2b Results on AD109, an Investigational Oral Drug for Obstructive Sleep Apnea, for the First Time at ATS 2023
21 mai 2023 10h00 HE | Apnimed, Inc.
-- New MARIPOSA Study Data Showed AD109 Statistically Significantly Improved Both Objective and Subjective Outcomes in OSA Patients -- MARIPOSA Results Support Advancing AD109 to Phase 3 CAMBRIDGE,...